Skip to main content

Table 2 The impact of isoniazid preventive therapy on the net cytokine responses at the end of six-months follow up among household contacts with latent tuberculosis infection

From: Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study

Cytokine Mean at end of six months Mean at end of six months Adjusted mean difference at the end of six monthsa P-value
  (pg/ml; 95 % CI) (pg/ml; 95 % CI) (pg/ml; 95 % CI)  
  No IPT (n = 17) IPT (n = 18)   
IFN-γ 2003.6(372.7, 3634.4) 541.1 (290.8, 791.3) −1488.6(−2682.5, −294.8) 0.01
IL-2 337.0(167.3, 506.8) 193.9 108.5, 279.3) −213.1(−419.2, −7.0) 0.04
TNF-α 34.4(−10.6, 79.4) 55.6(−6.3, 117.6) 34.1(−40.0, 108.2) 0.36
IL-5 15.5(−3.8, 34.9) 1.1(0.8, 1.4) −21.2 (−53.9, 11.3) 0.20
IL-13 35.4(−3.2, 74.2) 5.1(0.9, 9.4) −45.4(−104.4, 13.4) 0.13
IL-10 1.0(0.9, 1.1) 3.3(−0.8, 7.6) 2.0 (−1.43, 5.4) 0.25
IL-17a 2.4(−0.4, 5.2) 1.5(0.7, 2.3) 0.4 (−0.4, 1.2) 0.33
IL-17f 12.3(3.3, 21.3) 10.2(−6.1, 26.6) −5.8(−17.5, 5.7) 0.32
IL-21 34.0(−22.7, 90.7) 123.8(−133.9, 381.6) −11.6(−40.9, 17.5) 0.43
IL-22 27.0(1.3, 52.7) 6.1(−0.2, 12.6) −6.8(−88.8, 75.0) 0.86
  1. aThis is the expected value of the mean difference in cytokine level at six months, comparing participants who received IPT to those did not receive IPT, adjusting for the baseline level of the cytokine and the BCG scar status. Each cytokine was analysed in a separate model, with bootstrapping to estimate the confidence intervals
\